ArticleFrontiers in immunology2026
Serum IL-6 and functional outcome after endovascular therapy: the mediating role of infarct volume growth in acute ischemic stroke.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Inflammatory factors are pivotal in systemic and central nervous system inflammation post-stroke. This study examined if peripheral inflammatory factors were associated with outcomes after endovascular therapy for acute large vessel occlusion stroke by mediating infarct growth. Methods: We conducted a retrospective analysis of the EVTRNA (Circulating Non-coding RNA in Acute Ischemic Stroke with Endovascular Treatment) trial. Patients who underwent pre-endovascular therapy multimodal MRI, postoperative day 1 inflammatory factor testing, and postoperative day 7 head CT for infarct volume evaluation were included in this study. Unfavorable outcome was defined as a modified Rankin Scale score of 3-5 at the 90-day follow-up. Regression analysis and mediation analysis were employed to assess the association between inflammatory factors and clinical outcomes. Results: A total of 105 patients were included in this study, of whom 51 experienced unfavorable outcomes. Univariate analysis demonstrated that elevated interleukin-6 (IL-6) levels, higher baseline National Institutes of Health Stroke Scale scores at admission, increased fasting blood glucose levels, and infarct growth were all significantly associated with unfavorable outcomes. After adjustment by multivariate analysis, IL-6 (odds ratio 1.02, 95% confidence interval 1.01-1.03) and the other aforementioned factors remained independently associated with unfavorable outcomes. Further mediation analysis revealed that infarct volume growth partially accounts for the unfavorable prognosis observed in patients with elevated IL-6 levels. Conclusions: IL-6 was associated with unfavorable outcomes in patients undergoing endovascular therapy. Postoperative infarct volume growth partially mediated the effect of IL-6 on clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.